Mascarenhas, J., Baer, M., Kessler, C., Hexner, E., Tremblay, D., Price, L., . . . Hoffman, R. (2019). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leuk Lymphoma.
Citação norma ChicagoMascarenhas, J., et al. "Phase II Trial of Lestaurtinib, a JAK2 Inhibitor, in Patients With Myelofibrosis." Leuk Lymphoma 2019.
MLA CitationMascarenhas, J., et al. "Phase II Trial of Lestaurtinib, a JAK2 Inhibitor, in Patients With Myelofibrosis." Leuk Lymphoma 2019.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.